The purpose of this study is to find out whether human serum albumin works better than sodium chloride solution in helping the kidneys recover in patients who have both liver cirrhosis and kidney injury. The study will look at how many patients in each treatment group have their kidney function return to normal levels, which is measured by checking certain substances in the blood. The researchers will also examine whether the treatment helps patients avoid needing kidney replacement therapy, which is a treatment that does the work of the kidneys when they are not functioning properly.

During the study, patients will receive either human serum albumin or sodium chloride solution through an infusion into a vein over a period of two days. The study is described as open-label, which means both the patients and doctors will know which treatment is being given. The researchers will monitor various health measurements throughout the study, including blood tests to check kidney function, measurements of inflammation in the body, heart function using ultrasound images, and overall survival. The study will also track any unwanted effects that may occur during treatment. Patients will be followed for 28 days to see how well their kidneys recover and how their overall health progresses.

The purpose of this research is to determine if VS-01 can help treat overt hepatic encephalopathy when given once daily for up to 4 days. The study will compare two different treatment durations (3 hours and 4 hours) of VS-01 combined with standard care against standard care alone. The medication contains citric acid as its main component and is administered through intraperitoneal delivery, which means it is given directly into the abdominal cavity.

During the study, patients will receive either VS-01 with standard treatment or standard treatment alone. The treatment period lasts up to 4 days, during which doctors will monitor how quickly patients’ symptoms improve. The study will also look at how the body processes the medication and track any changes in blood and abdominal fluid composition to ensure the treatment is safe.

The purpose of this study is to evaluate how effective Carvedilol is in preventing digestive bleeding in patients with cirrhotic portal hypertension. Participants in the study will take Carvedilol at a dose of 12.5 mg per day. The study will last for about three months, during which the effects of the medication will be monitored. The main focus will be on measuring changes in the portosystemic gradient, which is a way to assess blood pressure changes in the portal vein, using a method called endoscopic ultrasound.

Throughout the study, researchers will also observe any side effects that participants may experience from taking Carvedilol. The study aims to determine if there is a significant reduction in the risk of digestive bleeding and to monitor any changes in biological and liver-related parameters. This information will help in understanding the potential benefits and risks of using Carvedilol for managing cirrhotic portal hypertension.

The purpose of the study is to evaluate whether this treatment can help slow down the progression of decompensated cirrhosis. Participants in the study will be randomly assigned to receive either the fecal microbiome capsules or a placebo, which looks like the treatment but does not contain the active ingredients. The study is designed to be double-blinded, meaning neither the participants nor the researchers will know who is receiving the actual treatment or the placebo, to ensure unbiased results.

Throughout the study, participants will be monitored for any changes in their condition, including the time it takes for any new complications of cirrhosis to occur. The study will also track other health outcomes, such as survival rates and the frequency of hospital visits due to cirrhosis complications. Participants will have regular check-ups over a period of time to assess their health and the effects of the treatment. The study aims to provide valuable insights into the potential benefits of fecal microbiome transplantation for people with decompensated cirrhosis.

The treatment being studied includes the use of Norfloxacin, an antibiotic that comes in tablet form. The purpose of the study is to evaluate how likely it is for patients to develop resistance to antibiotics within 28 days of starting treatment. This will be assessed by looking for new bacterial infections or colonizations that are resistant to multiple drugs, known as MDROs (multi-drug resistant organisms).

Participants in the study will receive either the conventional antibiotic treatment or the new strategy based on hospital bacteria monitoring. The study will track various outcomes, such as the development of antibiotic resistance, the resolution of infections, and the overall health and survival of the patients during their hospital stay and up to 28 days after treatment begins. The trial aims to provide insights into the best ways to manage bacterial infections in patients with decompensated cirrhosis, potentially improving treatment strategies and patient outcomes.

The purpose of the study is to determine if treatment with norfloxacin can reduce portal hypertension in patients with decompensated cirrhosis. Participants in the study will be randomly assigned to receive either norfloxacin or a placebo. The study will last for 12 weeks, during which time the effects of the treatment on portal hypertension will be monitored. The study is designed to be double-blinded, meaning neither the participants nor the researchers will know who is receiving the actual medication or the placebo, to ensure unbiased results.

Throughout the study, researchers will also observe the occurrence of liver-related complications and monitor various health indicators, such as biomarkers of bacterial translocation and systemic inflammation, as well as patient-reported outcomes related to quality of life. The study aims to provide valuable insights into the potential benefits of norfloxacin for patients with these liver conditions.

The purpose of this research is to determine how effective resmetirom is in preventing serious liver-related complications in patients with well-compensated NASH cirrhosis. The study will track important health events including liver-related problems, need for liver transplant, and changes in liver function.

During the study, which lasts up to 36 months, participants will take their assigned medication daily. Throughout this period, they will have regular check-ups to monitor their liver health. Various measurements will be taken, including blood tests to check cholesterol levels and special imaging tests to measure the amount of fat in the liver. The study uses MRI-PDFF (magnetic resonance imaging) to measure changes in liver fat content.

The purpose of this study is to evaluate the safety of these FMT capsules in treating immune activation in patients with cirrhosis and ascites. Participants will take the treatment or placebo orally in capsule form. The study will last for about three months, during which participants will have regular check-ups to monitor their health and any side effects. The study aims to see if the treatment can help reduce inflammation and improve liver function and quality of life.

Throughout the study, researchers will observe any serious adverse events and other side effects. They will also measure changes in inflammation markers, liver function scores, and quality of life assessments. The goal is to determine if the treatment is safe and potentially beneficial for patients with these liver conditions. Participants will be closely monitored to ensure their safety and well-being during the trial.

The purpose of this research is to determine if pegozafermin can help improve liver scarring and prevent the disease from getting worse in patients with MASH and cirrhosis. The study will look at how the liver tissue changes over time and track whether patients develop complications related to their liver disease.

During the study, participants will receive either pegozafermin injections or placebo. The treatment period will last for 60 months, during which patients will undergo various medical examinations to monitor their liver health. The maximum daily dose of pegozafermin that may be given is 30 milligrams, with a total maximum dose of 7200 milligrams over the entire study period.

The purpose of the study is to assess how these treatments affect the concentration of albumin in the blood and to evaluate their safety in patients who need long-term albumin treatment. Participants in the study will receive either the new albumin solution or the standard commercial albumin solution. The study will last for six months, during which time the participants’ health will be closely monitored. This includes checking vital signs, laboratory test results, and any side effects that may occur.

Throughout the study, researchers will also look for signs of how well the treatments are working by examining liver and kidney function, as well as other important health indicators. The goal is to determine if the new albumin solution is safe and effective for patients with decompensated cirrhosis, potentially offering a better treatment option for managing this challenging condition.

The purpose of this research is to determine if RTX001 is safe to use and how well patients tolerate the treatment. The study will involve collecting cells from the patient’s blood through a procedure called leukapheresis, processing these cells to create RTX001, and then giving the processed cells back to the patient through an intravenous infusion. Researchers will monitor patients for any side effects and track how their liver condition changes after receiving the treatment.

This is an early-phase study that will help researchers understand how this new cell therapy might work for patients with severe liver disease. The treatment approach is considered experimental, as it uses modified cells from the patient’s own immune system to potentially help improve liver function. Throughout the study, patients will have regular check-ups to monitor their health and assess how they respond to the treatment.

The treatment being tested in this study is called Human Serum Albumin, which is a protein derived from human blood. It is used in a solution form for infusion, meaning it is administered directly into the bloodstream through a vein. The specific product used in this trial is known as Albutein 50 g/l solution for infusion. The study aims to evaluate the effect of combining this treatment with standard medical care to see if it improves the 90-day survival rate of patients with ACLF.

Participants in the study will receive either the standard medical treatment alone or the standard treatment plus the Human Serum Albumin solution. The study will monitor the participants over a period to assess their overall survival and other health outcomes. The goal is to determine if the addition of the albumin solution can help improve the chances of survival for patients with this serious liver condition.

Participants in the study will receive either the combination of Zibotentan and Dapagliflozin, Zibotentan alone, or a placebo. The study will last for a period of six weeks, during which the effects of the treatments on body weight, body water volumes, and blood pressure will be monitored. The trial aims to see if the combination of medications can better manage symptoms compared to taking Zibotentan alone or a placebo.

Throughout the study, participants will be closely monitored for any changes in their condition, including any side effects or adverse events. The trial will help determine the safety and effectiveness of using Zibotentan and Dapagliflozin together for treating cirrhosis. This research could provide valuable insights into new treatment options for managing this liver condition.

The purpose of the study is to evaluate how effective and safe Belapectin is in preventing esophageal varices. Participants in the study will receive either Belapectin or a placebo. The study will last for about 18 months, during which time participants will receive regular injections and have their health monitored closely. The study aims to see if Belapectin can reduce the number of people who develop esophageal varices compared to those who receive a placebo.

Throughout the study, researchers will also look at other health outcomes, such as whether participants develop other complications related to liver disease, like variceal bleeding or ascites, which is fluid buildup in the abdomen. The study will help determine if Belapectin can be a beneficial treatment for people with NASH cirrhosis to prevent these serious complications.

The purpose of the study is to determine the time it takes for patients to experience their first unplanned re-hospitalization or death over a period of 12 months. Participants will be randomly assigned to either stop or continue their PPI treatment. The study will monitor various health outcomes, including any infections, liver-related complications, and changes in the gut bacteria over time.

Throughout the study, participants will be closely observed to gather information on their health status and any changes that occur. The trial aims to provide valuable insights into the effects of discontinuing long-term PPI therapy in individuals with liver cirrhosis, potentially guiding future treatment decisions for this condition.

The purpose of the study is to see if this new method can help patients develop a better immune response, measured by the level of antibodies in the blood, which are proteins that help fight infections. The study will follow participants over a period of six months, with vaccinations given at the start, one month, and six months. Researchers will check the antibody levels at different times to see how well the body is responding to the vaccine.

Participants will be divided into groups to receive either the traditional intramuscular vaccine, the intradermal vaccine, or the intradermal vaccine after applying the IMIQUIMOD cream. The study will also monitor any side effects from the treatments. The goal is to find out which method is most effective in helping cirrhotic patients who did not respond to the conventional vaccine regimen to develop protective levels of antibodies against Hepatitis B.

Participants in the study will be randomly assigned to receive either dapagliflozin or a standard treatment, which may include a placebo. The study will monitor the participants over a period of several months to observe any side effects and to assess the overall health outcomes. The study will also track the occurrence of specific complications related to liver cirrhosis, such as bleeding from veins in the esophagus, confusion due to liver failure (known as hepatic encephalopathy), and fluid buildup in the abdomen (ascites).

Throughout the study, various health markers will be measured to understand the impact of dapagliflozin on liver function and overall health. These include changes in scores that assess liver disease severity, quality of life, and other health indicators. The study aims to provide valuable information on whether dapagliflozin can be a safe and effective treatment option for people with decompensated liver cirrhosis.

The purpose of the study is to evaluate the safety and tolerability of this combination therapy in patients who are at high risk of poor outcomes due to their liver condition. Participants in the study will receive these treatments over a period of up to 90 days. The study will monitor for any side effects, such as pulmonary edema (fluid in the lungs), major bleeding, or thrombocytopenia (a condition where there is a low number of platelets in the blood, which can lead to bleeding).

Throughout the study, researchers will also track changes in the participants’ health, including their liver function, kidney function, and overall survival without the need for a liver transplant. The study aims to provide valuable information on whether this combination therapy can improve outcomes for patients with decompensated cirrhosis.

The purpose of this study is to validate a predictive biomarker, which is a biological indicator, to see how well patients with cirrhosis and a condition called ascites respond to human albumin therapy. Ascites is a complication of liver cirrhosis where fluid builds up in the abdomen. The study will observe patients over a period of time to see how the treatment affects their health, focusing on liver-related outcomes such as bleeding, infections, and kidney issues. The study will also look at the overall survival of patients over six months, the number of organ failures, and the quality of life of the participants.

Participants in the study will receive the treatment for a maximum of 26 weeks. During this time, researchers will monitor various health indicators to assess the effectiveness and safety of the treatment. The study aims to provide valuable insights into how personalized treatment with human albumin can benefit patients with liver cirrhosis and its complications, potentially improving their quality of life and health outcomes.

The purpose of this study is to monitor patients who have previously received at least one infusion of HepaStem in earlier clinical trials. The study aims to ensure that the treatment remains safe over a long period. Patients who have participated in these earlier studies will continue to be observed to check for any potential side effects or health changes. This includes looking out for serious events such as organ transplants, the development of tumors, or any diseases that might arise from infections or reactivation of dormant viruses.

Participants in this study will not receive any new treatments but will be regularly monitored to gather information about their health following their initial HepaStem treatment. This monitoring will help researchers understand the long-term effects of the therapy and ensure that it is safe for continued use in treating these liver-related conditions.

The purpose of the study is to validate a predictive biomarker, which is a biological indicator that can help predict how well a patient will respond to the human albumin therapy. The study will involve administering the treatment through an intravenous infusion, which means the solution is delivered directly into the bloodstream through a vein. Participants will receive the treatment over a period of time, and their health will be monitored to observe any changes or improvements in their condition.

Throughout the study, researchers will track various health outcomes, such as the number of liver-related complications, survival rates, and quality of life. They will also monitor any side effects or adverse reactions to the treatment. The study aims to provide valuable insights into the effectiveness of human albumin therapy for patients with liver cirrhosis and ascites, potentially leading to improved treatment strategies in the future.

The purpose of the study is to assess how these medications can affect the condition of patients with liver cirrhosis and portal hypertension. Participants will be randomly assigned to receive either the combination of Zibotentan and Dapagliflozin, Dapagliflozin alone, or a placebo. The study is designed to be double-blind, meaning neither the participants nor the researchers will know who is receiving which treatment, to ensure unbiased results. The trial will be conducted over a period of 16 weeks, during which the participants’ health and response to the treatment will be closely monitored.

Throughout the study, the main focus will be on measuring changes in a specific pressure in the liver, known as hepatic venous pressure gradient (HVPG), from the start of the study to the end. This measurement helps to understand the severity of portal hypertension and the effectiveness of the treatment. The study will also look at other health indicators, such as body weight and blood pressure, to evaluate the overall safety and tolerability of the medications. Participants will be required to take the medications orally, and their progress will be assessed at regular intervals to gather comprehensive data on the treatment’s impact.

Participants in the study will receive either Efruxifermin or a placebo, which is a substance with no active medication. The treatment is given as a solution for injection under the skin. The study will monitor participants over a period to see if Efruxifermin can improve liver health by reducing scarring and preventing the disease from getting worse. The main goal is to see if the treatment can help people live longer without experiencing serious liver-related problems.

The study will last for several years, with regular check-ups to assess the health of the liver and overall well-being of the participants. The researchers will look at various health markers, including liver function tests and other indicators of liver health, to determine the effectiveness of Efruxifermin compared to the placebo. This research is important for understanding how to better treat liver diseases like NASH and MASH and improve the quality of life for those affected.